| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 81 | Compositions and use thereof for treating symptoms of preeclampsia | US12047818 | 2008-03-13 | US08658163B2 | 2014-02-25 | Joan M. Fallon |
| A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and a method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using the presence of chymotrypsin in the maternal GI tract as a biomarker to determine the likelihood of developing preeclampsia, a pregnancy induced hypertension, and eclampsia/toxemia is disclosed. | ||||||
| 82 | METHOD FOR TREATING PERVASIVE DEVELOPMENT DISORDERS | US13481087 | 2012-05-25 | US20120230970A1 | 2012-09-13 | JOAN M. FALLON |
| A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. | ||||||
| 83 | Enzyme Delivery Systems and Methods of Preparation and Use | US13407408 | 2012-02-28 | US20120189703A1 | 2012-07-26 | Joan M. FALLON; Matthew HEIL |
| This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders. | ||||||
| 84 | Method for identifying individuals having a pervasive development disorder amenable to digestive enzyme therapy | US12487864 | 2009-06-19 | US08211661B2 | 2012-07-03 | Joan M. Fallon |
| A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration. In another aspect, a therapeutic method for treating an individual diagnosed with a PDD pervasive developmental disorder comprises determining the efficacy of secretin, other neuropeptides, peptides, and digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level. | ||||||
| 85 | METHOD FOR TREATING PERVASIVE DEVELOPMENT DISORDERS | US13313629 | 2011-12-07 | US20120114562A1 | 2012-05-10 | Joan M. FALLON |
| A method of utilizing the chymotrypsin level of an individual as a measure of the success of neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. A method for determining the efficacy of neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with neuropeptides, peptides, or digestive enzyme administration. | ||||||
| 86 | Methods for treating pervasive development disorders | US10681018 | 2003-10-08 | US08163278B2 | 2012-04-24 | Joan M. Fallon |
| A method of determining the efficacy of secretin, neuropeptides, peptides, and/or digestive enzymes for treatment of an individual diagnosed with a pervasive development disorder, such as autism, where the individual has an abnormal fecal chymotrypsin level and exhibits a lack of protein digestion. A sample of feces is obtained from the individual in order to determine a quantitative level of chymotrypsin in the sample. The quantitative level of chymotrypsin is used to determine the efficacy of treating the individual with secretin, neuropeptides, peptides, and/or digestive enzymes. If it is determined, based on the individual's fecal chymotrypsin level, that the individual would benefit from the administration of secretin, neuropeptides, peptides, and/or digestive enzymes, then the amount necessary to effect a change in the individual's autistic behavior is determined by the individual's fecal chymotrypsin level, age and weight. | ||||||
| 87 | Method for treating pervasive development disorders | US12283090 | 2008-09-08 | US08105584B2 | 2012-01-31 | Joan M. Fallon |
| A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration. In another aspect, a therapeutic method for treating an individual diagnosed with a PDD pervasive developmental disorder comprises determining the efficacy of secretin, other neuropeptides, peptides, and digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level. | ||||||
| 88 | Protein concentrates and isolates, and processes for the production thereof from toasted oilseed meal | US12927299 | 2010-11-10 | US20110287477A1 | 2011-11-24 | Qingnong Nelson Tang |
| Protein concentrates and protein isolates, in addition to processes for the production of protein concentrates and protein isolates, are disclosed. In particular, the disclosure relates to the removal of fiber from a toasted oilseed meal using low g-force centrifugation. | ||||||
| 89 | Methods of treating and diagnosing Parkinsons disease and related dysautonomic disorders | US12487868 | 2009-06-19 | US08012710B2 | 2011-09-06 | Joan M. Fallon |
| A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder. | ||||||
| 90 | Enzyme delivery systems and methods of preparation and use | US12386051 | 2009-04-13 | US20100260857A1 | 2010-10-14 | Joan Fallon; Matt Heil |
| This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders. | ||||||
| 91 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SYMPTOMS OF PRION DISEASES | US12573353 | 2009-10-05 | US20100092447A1 | 2010-04-15 | Joan M. Fallon |
| A therapeutic composition for the treatment of the symptoms of prion diseases and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of a prion disease, or the likelihood of an individual to develop a prion disease is disclosed. | ||||||
| 92 | METHOD FOR TREATING PERVASIVE DEVELOPMENT DISORDERS | US12487864 | 2009-06-19 | US20090286270A1 | 2009-11-19 | Joan M. Fallon |
| A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration. In another aspect, a therapeutic method for treating an individual diagnosed with a PDD pervasive developmental disorder comprises determining the efficacy of secretin, other neuropeptides, peptides, and digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level. | ||||||
| 93 | METHODS OF TREATING AND DIAGNOSING PARKINSONS DISEASE AND RELATED DYSAUTONOMIC DISORDERS | US12487868 | 2009-06-19 | US20090285790A1 | 2009-11-19 | Joan M. Fallon |
| A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder. | ||||||
| 94 | NOVEL PHARMACEUTICAL PREPARATION FOR PREECLAMPSIA, ECLAMPSIA, AND TOXEMIA, AND THEIR RELATED SYMPTOMS AND RELATED DISORDERS OF PREGNANCY | US12047818 | 2008-03-13 | US20090232789A1 | 2009-09-17 | Joan M. Fallon |
| A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the maternal GI tract to determine the likelihood of developing preeclampsia, pregnancy induced hypertension, and eclampsia/toxemia is disclosed. | ||||||
| 95 | Methods for treating pervasive development disorders | US11213255 | 2005-10-18 | US20060182728A1 | 2006-08-17 | Joan Fallon |
| A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration. In another aspect, a therapeutic method for treating an individual diagnosed with i PDD pervasive developmental disorder comprises determining the efficacy of secretin, other neuropeptides, peptides, and digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level. | ||||||
| 96 | Acne treatment with multifunctional enzyme | US600273 | 1996-02-08 | US5958406A | 1999-09-28 | Johan R. de Faire; Richard L. Franklin; John Kay; Ragnvald Lindblom |
| The invention relates to a multifunctional enzyme that can be derived from crustaceans or fish. The enzyme has at least one of a chymotrypsin, trypsin, elastase, collagenase and exo peptidase activity, and a molecular weight between about 20 kd and about 40 kd as determined by SDS PAGE. Preferably, the multifunctional enzyme has substantial anti cell-cell adhesion activity. Preferably, the multifunctional enzyme has substantial homology with the krill multifunctional enzyme. These enzymes are useful for treating viral infections such as herpes outbreaks, fungal, bacterial or parasitic infections, including the primary and secondary infections of leprosy, colitis, ulcers, hemorrhoids, corneal scarring, dental plaque, acne, cystic fibrosis, blood clots, wounds, immune disorders including autoimmune disease and cancer. Additionally, the invention relates to a method of purifying the multifunctional enzyme, and to a preparation of essentially purified multifunctional enzyme. | ||||||
| 97 | ENZYME FORMULATION FOR REDUCING SALICYLATE AND OTHER INTOLERANCE | EP16876422.3 | 2016-12-09 | EP3390647A1 | 2018-10-24 | Fournier, Thea |
| Disclosed is a formulation of the following enzymes: Beta Glucanase, Chymotrypsin, Phytase, Lactase, and Invertase, which has been found to be effective in treating salicylate intolerant people, and causing a significant improvement in a wide variety of pathologies and symptoms, including, but not limited to: stuttering, migraines, ADHD, behavioral deficits, Tourettes disease, seizures, autism (ASD), atrial fibrillation, anxiety, depression, joint pain, cognitive and perceptual disorders, respiratory difficulties and non-diabetic neuropathy. | ||||||
| 98 | DIGESTIVE ENZYME PREPARATION FOR ECLAMPSIA | EP16152319.6 | 2009-03-13 | EP3050571B1 | 2018-05-09 | FALLON, Joan M. |
| A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the maternal GI tract to determine the likelihood of developing preeclampsia, pregnancy induced hypertension, and eclampsia/toxemia is disclosed. | ||||||
| 99 | COMPOSITIONS COMPRISING PROTEASE, AMYLASE AND LIPASE FOR USE IN THE TREATMENT OF STAPHYLOCOCCUS AUREUS INFECTIONS | EP10729462.1 | 2010-01-06 | EP2373791B1 | 2016-03-30 | FALLON, Joan M.; HEIL, Matthew; FALLON, James J. |
| 100 | A NOVEL PHARMACEUTICAL PREPARATION FOR PREECLAMPSIA. | EP09719395.7 | 2009-03-13 | EP2257305B1 | 2016-03-09 | Fallon, Joan M. |
| A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the maternal GI tract to determine the likelihood of developing preeclampsia, pregnancy induced hypertension, and eclampsia/toxemia is disclosed. | ||||||
QQ群二维码
意见反馈
意见反馈